A perspective on “cure” for Rett syndrome
Abstract The reversal of the Rett syndrome disease process in the Mecp2 mouse model of Guy et al. (2007) has motivated families and researchers to work on this condition. The reversibility in adult mice suggests that there is potentially much to be gained from rational treatments applied to patients...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-018-0786-6 |
id |
doaj-e314279404264ecf95d272580b8e0976 |
---|---|
record_format |
Article |
spelling |
doaj-e314279404264ecf95d272580b8e09762020-11-24T21:25:15ZengBMCOrphanet Journal of Rare Diseases1750-11722018-04-011311510.1186/s13023-018-0786-6A perspective on “cure” for Rett syndromeAngus John Clarke0Ana Paula Abdala Sheikh1Institute of Medical Genetics, Division of Cancer & Genetics, School of Medicine, Cardiff UniversitySchool of Physiology, Pharmacology & Neuroscience, University of BristolAbstract The reversal of the Rett syndrome disease process in the Mecp2 mouse model of Guy et al. (2007) has motivated families and researchers to work on this condition. The reversibility in adult mice suggests that there is potentially much to be gained from rational treatments applied to patients of any age. However, it may be difficult to strike the right balance between enthusiasm on the one hand and realism on the other. One effect of this has been a fragmentation of the “Rett syndrome community” with some groups giving priority to work aimed at a cure while fewer resources are devoted to medical or therapy-based interventions to enhance the quality of life of affected patients or provide support for their families. Several possible therapeutic approaches are under development that, it is claimed and hoped, may lead to a “cure” for patients with Rett syndrome. While all have a rationale, there are potential obstacles to each being both safe and effective. Furthermore, any strategy that succeeded in restoring normal levels of MECP2 gene expression throughout the brain carries potential pitfalls, so that it will be of crucial importance to introduce any clinical trials of such therapies with great care. Expectations of families for a radical, rational treatment should not be inflated beyond a cautious optimism. This is particularly because affected patients with us now may not be able to reap the full benefits of a “cure”. Thus, interventions aimed at enhancing the quality of life of affected patients should not be forgone and their importance should not be minimised.http://link.springer.com/article/10.1186/s13023-018-0786-6MECP2Rett syndromeCureExpectationsGene therapyGene editing |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Angus John Clarke Ana Paula Abdala Sheikh |
spellingShingle |
Angus John Clarke Ana Paula Abdala Sheikh A perspective on “cure” for Rett syndrome Orphanet Journal of Rare Diseases MECP2 Rett syndrome Cure Expectations Gene therapy Gene editing |
author_facet |
Angus John Clarke Ana Paula Abdala Sheikh |
author_sort |
Angus John Clarke |
title |
A perspective on “cure” for Rett syndrome |
title_short |
A perspective on “cure” for Rett syndrome |
title_full |
A perspective on “cure” for Rett syndrome |
title_fullStr |
A perspective on “cure” for Rett syndrome |
title_full_unstemmed |
A perspective on “cure” for Rett syndrome |
title_sort |
perspective on “cure” for rett syndrome |
publisher |
BMC |
series |
Orphanet Journal of Rare Diseases |
issn |
1750-1172 |
publishDate |
2018-04-01 |
description |
Abstract The reversal of the Rett syndrome disease process in the Mecp2 mouse model of Guy et al. (2007) has motivated families and researchers to work on this condition. The reversibility in adult mice suggests that there is potentially much to be gained from rational treatments applied to patients of any age. However, it may be difficult to strike the right balance between enthusiasm on the one hand and realism on the other. One effect of this has been a fragmentation of the “Rett syndrome community” with some groups giving priority to work aimed at a cure while fewer resources are devoted to medical or therapy-based interventions to enhance the quality of life of affected patients or provide support for their families. Several possible therapeutic approaches are under development that, it is claimed and hoped, may lead to a “cure” for patients with Rett syndrome. While all have a rationale, there are potential obstacles to each being both safe and effective. Furthermore, any strategy that succeeded in restoring normal levels of MECP2 gene expression throughout the brain carries potential pitfalls, so that it will be of crucial importance to introduce any clinical trials of such therapies with great care. Expectations of families for a radical, rational treatment should not be inflated beyond a cautious optimism. This is particularly because affected patients with us now may not be able to reap the full benefits of a “cure”. Thus, interventions aimed at enhancing the quality of life of affected patients should not be forgone and their importance should not be minimised. |
topic |
MECP2 Rett syndrome Cure Expectations Gene therapy Gene editing |
url |
http://link.springer.com/article/10.1186/s13023-018-0786-6 |
work_keys_str_mv |
AT angusjohnclarke aperspectiveoncureforrettsyndrome AT anapaulaabdalasheikh aperspectiveoncureforrettsyndrome AT angusjohnclarke perspectiveoncureforrettsyndrome AT anapaulaabdalasheikh perspectiveoncureforrettsyndrome |
_version_ |
1725983931698774016 |